EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Analysis of ocular adverse events associated with SNRIs

Zhengtai Sun, Yuting Liu, LiJuan Que

Frontiers in Pharmacology · 29.05.2026 · 17

DOI: 10.3389/fphar.2026.1837592 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 29.05.2026. Verfasst von Zhengtai Sun und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, The First Affiliated Hospital of Soochow University, Suzhou, China. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Serotonin-norepinephrine reuptake inhibitors (SNRIs) are widely used in the treatment of neuropsychiatric disorders and chronic pain; however, their comprehensive ocular safety profile has not been systematically evaluated. This study aimed to investigate and compare the safety signals of ocular adverse events (AEs) associated with five major SNRIs (venlafaxine, duloxetine, desvenlafaxine, milnacipran, and levomilnacipran).

Methods

This was a retrospective pharmacovigilance analysis. Ocular AEs associated with the SNRIs were extracted from the FAERS database (Q1 2004-Q4 2024). Disproportionality analyses were conducted using four algorithms, proportional reporting ratio (PRR), reporting odds ratio (ROR), Bayesian confidence propagation neural network (BCPNN), and multi-item gamma Poisson shrinker (MGPS), to identify statistically significant signals. Time-to-onset analysis and sex subgroup analyses were also performed.

Results

A total of 5,860 SNRI-related ocular AEs were included. At the System Organ Class level, no significant positive signals of ocular AEs were observed. At the Preferred Term (PT) level, distinct risk profiles emerged for different SNRIs. Mydriasis was one of the strongest and most common signals for duloxetine, desvenlafaxine, and venlafaxine. Venlafaxine was also strongly associated with anisocoria and accommodation disorder. Vision blurred and visual impairment were the most frequently reported Preferred Term across all drugs. TTO analysis revealed that AEs occurred later for levomilnacipran (median 161 days) and venlafaxine (median 147 days), but earlier for desvenlafaxine (31 days) and milnacipran (11.5 days). Sex subgroup analyses revealed significant differences.

Conclusion

Based on real-world data, this study identified drug-specific and sex-specific differences in the ocular safety signals of SNRIs. Mydriasis represents a common strong risk signal across multiple SNRIs.

Schlagwörter

Stichwörter der Autor:innen

FDA adverse event reporting systemocular adverse eventspharmacovigilanceserotonin-norepinephrine reuptake inhibitorssex differences

Autor:innen und Institutionen

  • Department of Ophthalmology, The First Affiliated Hospital of Soochow University, Suzhou, China.

Zitieren

APA

Sun, Z., Liu, Y., & Que, L. (2026). Analysis of ocular adverse events associated with SNRIs. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1837592

Vancouver

Sun Z, Liu Y, Que L. Analysis of ocular adverse events associated with SNRIs. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1837592

BibTeX
@article{Sun2026,
  author = {Sun, Zhengtai and Liu, Yuting and Que, LiJuan},
  title = {Analysis of ocular adverse events associated with SNRIs},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1837592}
}
Kostenlos starten →